Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1112-1119, 2006. First published April 13, 2006; 10.1373/clinchem.2005.065490
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.065490v1
52/6/1112    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bieglmayer, C.
Right arrow Articles by Niederle, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bieglmayer, C.
Right arrow Articles by Niederle, B.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2006;52:1112-1119.)
© 2006 American Association for Clinical Chemistry, Inc.

Endocrinology and Metabolism

Parathyroid Hormone Monitoring during Total Parathyroidectomy for Renal Hyperparathyroidism: Pilot Study of the Impact of Renal Function and Assay Specificity

Christian Bieglmayer1,a, Klaus Kaczirek2, Gerhard Prager2 and Bruno Niederle2

1 Clinical Institute for Medical and Chemical Laboratory Diagnostics, and2 Section of Surgical Endocrinology, Division of General Surgery, General Hospital of the Medical University and City of Vienna, Vienna, Austria.

aAddress correspondence to this author at: Clinical Institute for Medical and Chemical Laboratory Diagnostics, EB05, General Hospital of the Medical University and City of Vienna, Waeringer Guertel 18-20, A 1090 Vienna, Austria. Fax 43-1-40400-6752; e-mail christian.bieglmayer{at}meduniwien.ac.at.

Background: Commonly used assays for intact parathyroid hormone (iPTH) detect not only the biologically active 84–amino acid hormone [PTH(1–84)], but cross-react with an N-terminal–truncated fragment. Because iPTH assays often fail to predict success of parathyroidectomy in patients with renal hyperparathyroidism (rHPT), we compared results of a 3rd-generation PTH(1–84) assay (Bio-iPTH; Nichols Institute Diagnostics) with two 2nd-generation iPTH assays (from Nichols and Roche Diagnostics) by evaluating the PTH clearance kinetics during surgical treatment.

Methods: We collected blood samples in short time intervals from 35 consecutive surgical patients with rHPT. Three patients had to be excluded from further calculations; the remainder were grouped according to kidney function and postoperative outcome. All samples were analyzed with the 3 automated PTH assays, which have different specificities.

Results: Twenty minutes after removal of the last gland, the PTH(1–84) values decreased to within the reference intervals in all patients with total and subtotal resection; however, iPTH concentrations normalized in only one half of these patients. In patients with poor renal function, the half-life of PTH(1–84) was shorter than the half-lives obtained with the iPTH assays.

Conclusions: The accuracy of PTH monitoring during surgery for rHPT depends on renal function and assay specificity. All assays tested showed similar effectiveness in detecting missed glands, but the assay for PTH(1–84) gave more reliable results than the iPTH assays, which overestimated the concentration of PTH and hampered the intrasurgical diagnosis of resection sufficiency.




The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J EndocrinolHome page
S.-K. Meyer, M. Zorn, K. Frank-Raue, M. W Buchler, P. Nawroth, and T. Weber
Clinical impact of two different intraoperative parathyroid hormone assays in primary and renal hyperparathyroidism
Eur. J. Endocrinol., February 1, 2009; 160(2): 275 - 281.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Q. Khan, O. S. Dhillon, R. J. O'Brien, J. Struck, P. A. Quinn, N. G. Morgenthaler, I. B. Squire, J. E. Davies, A. Bergmann, and L. L. Ng
C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study
Circulation, April 24, 2007; 115(16): 2103 - 2110.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.